Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment

(2022) Yan Hu et al.   JAMA Network Open

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

(2022) Oskar Hansson et al.   Alzheimers & Dementia

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease

(2021) Elisabeth H. Thijssen et al.   Scientific Reports

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

(2021) D. O. T. Alawode et al.   JOURNAL OF INTERNAL MEDICINE

Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances

(2021) Joyce R. Chong et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

(2021) Nicholas C. Cullen et al.   Nature Communications

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

(2021) Shorena Janelidze et al.   JAMA Neurology

Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

(2021) Inge M. W. Verberk et al.   Alzheimers & Dementia

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

(2021) Yan Li et al.   NEUROLOGY

Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision

(2020) Hendrik Neubert et al.   CLINICAL CHEMISTRY

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale

(2018) Sylvain Lehmann et al.   Frontiers in Aging Neuroscience

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

(2018) Armand Perret-Liaudet et al.   JOURNAL OF ALZHEIMERS DISEASE

Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8

(2018) Ibtisam Baghallab et al.   JOURNAL OF ALZHEIMERS DISEASE

Blood-based biomarkers for Alzheimer’s disease—An update

(2018) Henrik Zetterberg   JOURNAL OF NEUROSCIENCE METHODS

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

(2018) Harald Hampel et al.   Nature Reviews Neurology

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

(2015) Courtney L. Sutphen et al.   JAMA Neurology

mixtools: AnRPackage for Analyzing Finite Mixture Models

(2015) Tatiana Benaglia et al.   Journal of Statistical Software

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

(2014) Frank Jessen et al.   Alzheimers & Dementia

Tau PET Imaging in Alzheimer’s Disease

(2014) Nobuyuki Okamura et al.   Current Neurology and Neuroscience Reports

Novel plasma biomarker surrogating cerebral amyloid deposition

(2014) Naoki KANEKO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

(2013) Alan Rembach et al.   Alzheimers & Dementia

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Single molecule enzyme-linked immunosorbent assays: Theoretical considerations

(2012) Lei Chang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

The clinical use of structural MRI in Alzheimer disease

(2010) Giovanni B. Frisoni et al.   Nature Reviews Neurology

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology